Acute Coronary Syndromes (ACS) and Treatment Options Quiz

Chest pain or discomfort is a common and characteristic symptom of acute coronary syndrome.

Morphine is commonly used as the first-line medication for pain relief in acute coronary syndrome.

Regular exercise is not a risk factor for acute coronary syndrome; in fact, it is associated with a reduced risk.

Troponin levels are typically elevated in acute myocardial infarction due to myocardial damage.

Heparin is commonly used as an adjunct to fibrinolytic therapy to prevent further clot formation and improve outcomes in ST-elevation myocardial infarction (STEMI).

Bleeding, including intracranial hemorrhage, is a potential complication of thrombolytic therapy in acute coronary syndrome due to the increased risk of bleeding associated with thrombolysis.

Troponin is the preferred enzyme for diagnosing acute myocardial infarction due to its high specificity.

ST-segment elevation on ECG is a characteristic finding in ST-elevation myocardial infarction (STEMI).

Cardiogenic shock is a potential complication of acute coronary syndrome, often due to extensive myocardial damage.

The primary goal of reperfusion therapy is to restore blood flow to the ischemic area of the heart, minimizing myocardial damage.

Coronary angiography is commonly used to evaluate coronary artery anatomy and identify blockages in acute coronary syndrome.

Unstable angina typically presents as chest pain that is not fully relieved by rest or nitroglycerin.

Aspirin is the recommended first-line antiplatelet therapy in acute coronary syndrome to prevent further clot formation.

Clopidogrel is a commonly used P2Y12 inhibitor in the management of acute coronary syndrome.

Hemorrhagic stroke is a potential complication of thrombolytic therapy due to its risk of causing bleeding.

Cardiac tamponade is a potential complication of percutaneous coronary intervention due to perforation of the heart or a coronary artery.

Statins are used in the management of acute coronary syndrome to decrease LDL cholesterol levels and stabilize atherosclerotic plaques, reducing the risk of further cardiovascular events.

Abciximab is a glycoprotein IIb/IIIa inhibitor commonly used in the treatment of acute coronary syndrome to prevent platelet aggregation and thrombus formation.